S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
New CBOE “special perk” helps traders target income every weekend (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
New CBOE “special perk” helps traders target income every weekend (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
New CBOE “special perk” helps traders target income every weekend (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
New CBOE “special perk” helps traders target income every weekend (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months

Ocugen (OCGN) Stock Price, News & Analysis

$0.39
0.00 (-0.23%)
(As of 12/8/2023 08:57 PM ET)
Compare
Today's Range
$0.39
$0.40
50-Day Range
$0.36
$0.45
52-Week Range
$0.35
$1.62
Volume
797,600 shs
Average Volume
5.04 million shs
Market Capitalization
$99.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Ocugen MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
800.7% Upside
$3.50 Price Target
Short Interest
Bearish
9.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.30) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

824th out of 942 stocks

Biological Products, Except Diagnostic Industry

141st out of 157 stocks


OCGN stock logo

About Ocugen Stock (NASDAQ:OCGN)

Ocugen, Inc. is a biopharmaceutical company founded in 2013, dedicated to developing and commercializing innovative therapies to treat rare eye diseases and other disorders. With a mission to improve patients' lives through cutting-edge research and development, Ocugen is focused on creating transformative treatments that address unmet medical needs.

Headquartered in Malvern, Pennsylvania, Ocugen operates with a global mindset. The company leverages strategic partnerships and collaborations to advance its research and deliver its products worldwide. Ocugen's commitment to innovation and patient-centric solutions has earned it a reputation as a trusted leader in the biotechnology industry.

Ocugen's primary focus is developing gene therapies and biologics for treating rare eye diseases such as inherited retinal disorders and dry eye disease. By harnessing the potential of genetic medicine, Ocugen aims to provide patients with groundbreaking treatments that can significantly improve their quality of life. The company is also actively researching and developing vaccines, including a COVID-19 vaccine candidate.

The target market for Ocugen's products and services includes patients globally suffering from rare eye diseases. By addressing these underserved markets, Ocugen is poised to significantly impact the lives of patients who previously had limited treatment options.

Key customers of Ocugen include healthcare providers, hospitals, clinics, and patients. Ocugen's focus on building solid relationships with key stakeholders has allowed the company to gain traction and establish itself as a trusted partner in the healthcare ecosystem.

In terms of recent achievements, Ocugen has made remarkable progress. The company's most notable milestone was the advancement of its COVID-19 vaccine candidate, COVAXIN, in collaboration with Bharat Biotech. COVAXIN gained emergency use authorization in several countries, including India, and demonstrated promising efficacy against emerging virus variants. This achievement solidified Ocugen's position as a key player in the fight against the COVID-19 virus.

The management team at Ocugen comprises accomplished individuals with diverse backgrounds and extensive industry experience. Dr. Shankar Musunuri, the Chairman, Chief Executive Officer, and Co-Founder, is a seasoned entrepreneur with a successful track record in the biotechnology sector. His leadership has been instrumental in guiding the company's strategic vision and driving its growth. 

Regarding financial performance, Ocugen has not yet achieved profitability, and the stock has continued to drop because the FDA continues to place hold statuses on its developing vaccine and drugs. However, Ocugen's debt levels remain manageable, enabling the company to invest in research and development initiatives without compromising its long-term financial stability. 

Analyzing the company's valuation metrics is crucial in understanding its market positioning. Compared to industry peers, Ocugen's price-to-earnings ratio demonstrates the market's positive sentiment toward the company's growth prospects. Several factors influence the company's valuation. Firstly, the successful advancement of Ocugen's product pipeline, particularly its gene therapies and biologics, contributes to investor optimism. These innovative treatments could revolutionize the field of ophthalmology and address unmet medical needs.

Furthermore, the company's collaboration with Bharat Biotech on the development of COVAXIN has garnered significant attention. The emergency use authorization and promising efficacy data of COVAXIN have positioned Ocugen as a critical player in the global fight against COVID-19 and generated investor confidence in the company's ability to deliver effective vaccines.

However, it's important to note that external factors beyond the company's control can also influence stock prices, such as market conditions, investor sentiment toward the broader biotechnology industry, or geopolitical events. Therefore, thorough analysis and market performance monitoring are essential to understanding Ocugen's stock dynamics.

The biotechnology sector is highly competitive and constantly evolving. Ocugen operates within a niche market of rare eye diseases and genetic therapies, facing both established pharmaceutical companies and emerging biotechnology startups as competitors. Ocugen must maintain a competitive edge by leveraging its innovative technologies, strong research capabilities, and strategic collaborations.

Regulatory and political factors also play a significant role in the biotechnology industry. Changes in regulations or government policies related to drug development, intellectual property rights, or pricing can impact the industry landscape. Ocugen must stay abreast of these developments to ensure compliance and mitigate potential risks.

Looking ahead, Ocugen has several growth opportunities on the horizon. The successful commercialization of its pipeline products has the potential to drive substantial revenue growth. Additionally, the company can explore expansion into new markets and indications, leveraging its expertise in genetic medicine to target other rare diseases beyond ophthalmology.

Furthermore, strategic acquisitions or partnerships with other biotechnology companies can enhance Ocugen's product portfolio and expand its reach. Ocugen can capitalize on its strengths and propel its long-term success by actively pursuing these growth opportunities.

The biotechnology industry has risks and challenges. Market volatility, clinical trial failures, regulatory hurdles, and pricing pressures are among the key risks that Ocugen faces. The company must employ robust risk management strategies to mitigate these challenges effectively.

Ocugen's risk management approach should include diversification of its product pipeline, a thorough evaluation of clinical trial protocols, and proactive engagement with regulatory authorities to navigate the complex regulatory landscape. Furthermore, a comprehensive understanding of the competitive environment and monitoring market trends are crucial to adapt to changing market dynamics.

OCGN Stock Price History

OCGN Stock News Headlines

Ocugen (NASDAQ:OCGN) Shares Down 2.1%
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Ocugen (OCGN) Q3 2023 Earnings Call Transcript
Recap: Ocugen Q3 Earnings
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Ocugen Inc OCGN
Why Is Ocugen (OCGN) Stock Up 5% Today?
See More Headlines
Receive OCGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCGN
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$5.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+800.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-81,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$42.62 million
Book Value
$0.38 per share

Miscellaneous

Free Float
247,576,000
Market Cap
$99.68 million
Optionable
Not Optionable
Beta
3.93
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Shankar Musunuri M.B.A. (Age 59)
    Ph.D., Co-Founder, CEO & Chairman
    Comp: $1.2M
  • Dr. Uday B. Kompella Ph.D. (Age 56)
    Co-founder & Independent Director
    Comp: $56.72k
  • Mr. Michael Breininger CPA (Age 41)
    M.B.A., Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller
  • Dr. Arun Upadhyay Ph.D. (Age 41)
    Chief Scientific Officer and Head of Research, Development & Medical
  • Ms. Tiffany J. Hamilton M.B.A.
    Head of Corporate Communications
  • Mr. Michael Shine M.B.A.
    Senior Vice President of Commercial
  • Ms. Jyothy Pillai M.S.
    Head of Regulatory & Quality














OCGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Ocugen stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCGN shares.
View OCGN analyst ratings
or view top-rated stocks.

What is Ocugen's stock price target for 2024?

4 equities research analysts have issued 1 year price objectives for Ocugen's shares. Their OCGN share price targets range from $2.00 to $5.00. On average, they anticipate the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 800.7% from the stock's current price.
View analysts price targets for OCGN
or view top-rated stocks among Wall Street analysts.

How have OCGN shares performed in 2023?

Ocugen's stock was trading at $1.30 on January 1st, 2023. Since then, OCGN shares have decreased by 70.1% and is now trading at $0.3886.
View the best growth stocks for 2023 here
.

When is Ocugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our OCGN earnings forecast
.

How were Ocugen's earnings last quarter?

Ocugen, Inc. (NASDAQ:OCGN) issued its earnings results on Thursday, November, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02.

What ETF holds Ocugen's stock ?

Invesco Nasdaq Future Gen 200 ETF holds 76,301 shares of OCGN stock, representing 0.63% of its portfolio.

What other stocks do shareholders of Ocugen own?
Who are Ocugen's major shareholders?

Ocugen's stock is owned by a number of institutional and retail investors. Top institutional investors include Luminus Management LLC (1.06%), FMR LLC (0.07%), Charles Schwab Investment Management Inc. (0.07%), Bank of New York Mellon Corp (0.03%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Christopher Dold, Daniel Purefoy, Junge Zhang, Kirsten Castillo, Manish Potti, Prabhavathi Fernandes, Ramesh Kumar, Sanjay Subramanian, Shankar Musunuri, Uday Kompella and Vijay Tammara.
View institutional ownership trends
.

How do I buy shares of Ocugen?

Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OCGN) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -